Neurophysiological and clinical responses to rituximab in patients with anti-MAG polyneuropathy

Clinical Neurophysiology

Volumn 122, Issue 12, 2011, Pages 2518-2522

  Zara, Gabriella ^a   Zambello, Renato ^a   Ermani, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Anti MAG polyneuropathy; CD20 B lymphocytes; Disability scale; Electrodiagnostic studies; INCAT sensory sum score; Rituximab

Indexed keywords

ANTIBODY; CD20 ANTIGEN; IMMUNOGLOBULIN M; MYELIN ASSOCIATED GLYCOPROTEIN; MYELIN ASSOCIATED GLYCOPROTEIN ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BRAIN ELECTROPHYSIOLOGY; CLINICAL ARTICLE; CLINICAL EVALUATION; DEMYELINATING DISEASE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOMODULATION; MALE; MYELIN ASSOCIATED GLYCOPROTEIN ANTIBODY POLYNEUROPATHY; NEUROPHYSIOLOGY; POLYNEUROPATHY; PRICK TEST; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; SCORING SYSTEM; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; HUMANS; IMMUNOGLOBULIN M; IMMUNOLOGIC FACTORS; LECTINS; MALE; MIDDLE AGED; MYELIN-ASSOCIATED GLYCOPROTEIN; POLYNEUROPATHIES; TREATMENT OUTCOME;

EID: 80855138751     PISSN: 13882457     EISSN: 18728952     Source Type: Journal    
DOI: 10.1016/j.clinph.2011.05.015     Document Type: Article

References (37)

1. Benedetti L., Briani C., Grandis M., Vigo T., Gobbi M., Ghiglione E., et al. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst 2007, 12:102-107.
2. Benedetti L., Briani C., Franciotta D., Fazio R., Paolasso I., Comi C., et al. Rituximab in patients with chronic inflammatory polyradiculoneuropathy: a report of 13 cases, review of literature. J Neurol Neursurg Psychiatry 2011, 82(3):306-308.
3. Brannagan T.H. Current treatments of chronic immune-mediated demyelinating polyneuropathies. Muscle Nerve 2009, 39(5):563-578.
4. Broglio L., Lauria G. Worsening after rituximab treatment in anti-mag neuropathy. Muscle Nerve Letter to the Editor Sept 2005, 378-379.
5. Capasso M., Torrieri F., Di Muzio A., De Angelis M.V., Lugaresi A., Uncini A. Can electrophysiology differentiate polyneuropathy with anti-MAG/SGPG antibodies from chronic inflammatory demyelinating polyneuropathy?. Clin Neurophysiol 2002, 113(3):346-353.
6. Caudie C., Bouhour F., Petiot P., Gonnaud P.M., Antoine J.C., Vial C. Diagnostic value of the anti-IgM SGPG Elisa (Bühlmann laboratories AG) in 147 sera with monoclonal IgM. antiMAG/SGPG antibody-associated neuropathy. Ann Biol Clin (Paris) 2007, 65(4):369-375.
7. Chassande B., Leger J.M., Ben Younes-Chennoufi A., Bengoufa D., Maisonobe T., Bouche P., Baumann N. Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases. Muscle Nerve 1998, 21:55-62.
8. Dalakas M.C. B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target. Pharmacol Ther 2006, 112(1):57-70.
9. Dalakas M.C. Invited article: inhibition of B cell functions: implications for neurology. Neurology 2008, 70(23):2252-2260.
10. Dalakas M.C., Rakocevic G., Salajegheh M., Dambrosia J.M., Hahn A.F., Raju R., McElroy B. Placebo-controlled trial of Rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 2009, 65:286-293.
11. Dalakas M.C. Pathogenesis and treatment of Anti-Mag Neuropathy. Curr Treat Options Neurol 2010, 12(2):71-83.
12. Eurelings M., Moons K.G.M., Notermans N.C., Sasker L.D., De Jager A.E.J., Wintzen A.R., et al. Neuropathy and IgM M-proteins: Prognostic value of antibodies to MAG, SGPG and sulfatide. Neurology 2001, 56(2):228-233.
13. Finsterer J. Treatment of immune mediated, dysimmune neuropathies. Acta Neurol Scand 2005, 112(2):115-125.
14. Gabriel J.M., Erne B., Miescher G.C., Miller S.L., Vital A., Vital C., et al. Selective loss of myelin-associated glycoprotein from myelin correlates with anti-MAG antibody titre in demyelinating paraproteinemic polyneuropathy. Brain 1996, 119:775-787.
15. Hadden R.D.M., Nobile-Orazio E., Sommer C., Hahn A., Morra E., Pollard J., et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006, 13:809-818.
16. Hays A.P., Latov N., Takatsu M., Sherman W.H. Experimental demyelination of nerve induced by serum of patients with neuropathy and anti-MAG IgM M-protein. Neurology 1987, 37:242-256.
17. Hughes R., Bensa S., Willison H., van den Bergh P., Comi G., Illa I., et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001, 50:195-201.
18. Kaku D.A., England J.D., Sumner A.J. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain 1994, 117:941-947.
19. Kimura J. Electrodiagnostic in disease of the nerve and muscle: principle and practise. Philadelphia: FA Davis:1989. p. 103-138.
20. Kleyweg R.P., van der Meche F.G.A., Schmitz P.I.M. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991, 14:1103-1109.
21. Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol 1995, 37(Suppl. 1):S32-S42.
22. Latov N., Sherman W.H., Vlahides G. Therapy of neuropathy associated with anti-MAG IgM monoclonal gammopathy with rituximab. Neurology 1999, 52(Suppl. 2):A551.
23. Levine T.D., Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 1999, 52:1701-1704.
24. Martina I.S., van Koningsveld R., Schmitz P.I. Van der Meche FG, van Doorn PA. Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. J Neurol Neurosurg Psychiatry 1998, 65(5):743-747.
25. Merkies I.S.J., Schmitz P.I.M., van der Meche F.G.A., van Doorn P.A. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Neurology 2000, 54(4):943-949.
26. Merkies I.S.J., Schmitz P.I.M., van der Meche F.G.A., Samijn J.P.A., van Doorn P.A. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2002, 72:596-601.
27. Merkies I.S.J., Schmitz P.I.M., van der Meche F.G.A., van Doorn P.A. Comparison between impairment and disability scales in immune-mediate polyneuropathies. Muscle Nerve 2003, 28:93-100.
28. Merkies I.S.J., Schmitz P.I.M. Van der Meche FGA, Samijn JP, van Doorn PA; Inflammatory Neuropathy Cause and Treatment (INCAT) Group. J Neurol Neurosurg Psychiatry 2003, 74(1):99-104.
29. Nobile-Orazio E., Manfredini E., Carpo M., Meucci N., Monaco S., Ferrari S. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 1994, 36:416-424.
30. Noronha V., Fynan T.M., Duffy T. Flare in neuropathy following rituximab therapy for Waldenstrom's Macroglobulinemia. J Clin Oncol 2006, 24:e3.
31. Rech J., Hueber A.J., Kallert S., Leipe J., Kalden J.R., Beck M., et al. Remission of demyelinating polyneuropathy with immunoadsorption, low dose corticosteroids and anti-CD20 monoclonal antibody. Ther Apher Dial 2008, 12(3):205-208.
32. Renaud S., Gregor M., Fuhr P., Lorenz D., Deuschl G., Gratwohl A., et al. Rituximab in the treatment of polyneuropathy associated with anti-mag antibodies. Muscle Nerve 2003, 27:611-615.
33. Renaud S., Fuhr P., Gregor M., Schweikert K., Lorenz D., Daniels C., et al. High-dose rituximab and anti-MAG associated polyneuropathy. Neurology 2006, 66:742-744.
34. Steck A.J., Stalder A.K., Renaud S. Anti-myelin-associated glycoprotein neuropathy. Neurology 2006, 19(5):458-463.
35. Tracy J.A., Dick P.J. Investigations and treatment of chronic inflammatory demyelinating polyradiculoneuropathy and other inflammatory demyelinating polyneuropathies. Curr Opin Neurol 2010, 23(3):242-248.
36. Trojaborg W., Hayas A.P., Van den Berg L., Younger D.S., Latov N. Motor conduction parameters associated with anti-MAG antibodies and other types of demyelinating and axonal neuropathies. Muscle Nerve 1995, 18(7):730-735.
37. Zivković S.A. Rituximab in the treatment of peripheral neuropathy associated with monoclonal gammopathy. Expert Rev Neurother 2006, 6(9):1267-1274.